Frankfurt
22.05.26 | 09:55
4,040 Euro
-3,58 % -0,150
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | PolyPid Q1 2026 Earnings Call: Complete Transcript | 5 | Benzinga.com | ||
| 13.05. | PolyPid GAAP EPS of -$0.35 beats by $0.08 | 1 | Seeking Alpha | ||
| 13.05. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results | 117 | GlobeNewswire (Europe) | Initiated NDA Submission to the FDA for D-PLEX100; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA... ► Artikel lesen | |
| 13.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 28.04. | PolyPid to present wound infection data at surgery conference | 1 | Investing.com | ||
| 28.04. | PolyPid Ltd.; DPLEX: PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 13.04. | PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global | 2 | Investing.com | ||
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 13.04. | PolyPid Ltd.: PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX100 Sustained Local Release at ESCMID Global 2026 | 1 | GlobeNewswire (USA) | ||
| 08.04. | EQS-News: PolyPid vor dem Durchbruch? Warum dieses Biotech-Unternehmen plötzlich in den Fokus rückt (FSE: 2PV) | 402 | EQS Group (DE) | EQS-News: PolyPid
/ Schlagwort(e): Sonstiges
PolyPid vor dem Durchbruch? Warum dieses Biotech-Unternehmen plötzlich in den Fokus rückt (FSE: 2PV)
08.04.2026 / 17:45 CET/CEST
Für... ► Artikel lesen | |
| 01.04. | XFRA NEW INSTRUMENTS AVAILABLE ON 01.04.2026 | 331 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.04.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.04.2026
Aktien
1 SE0010600106 Infrea AB
2 SE0010441139... ► Artikel lesen | |
| 31.03. | PolyPid Ltd.: PolyPid Initiates D-PLEX100 NDA Submission to the FDA | 225 | GlobeNewswire (Europe) | PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31... ► Artikel lesen | |
| 31.03. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.03. | PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application | 1 | Investing.com | ||
| 17.03. | PolyPid Ltd.: PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX100's New Drug Application | 318 | GlobeNewswire (Europe) | FDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17... ► Artikel lesen | |
| 25.02. | PolyPid Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 11.02. | PolyPid Ltd. Bottom Line Falls In Q4 | 1 | RTTNews | ||
| 11.02. | PolyPid GAAP EPS of -$0.41 misses by $0.08 | 2 | Seeking Alpha | ||
| 11.02. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | 303 | GlobeNewswire (Europe) | The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX100 Positive FDA Pre-NDA Feedback Supports Rolling NDA Review- Submission Expected to Begin by the End of the... ► Artikel lesen | |
| 10.02. | Preview: PolyPid's Earnings | 1 | Benzinga.com | ||
| 04.02. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,00 | +2,17 % | Ihre wichtigsten Termine: Alle Blicke auf: Fraport, Biontech, Nagarro, Freenet & Intercontinental Exchange | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
| EVOTEC | 5,160 | +1,57 % | KAUFKURSE bei Renk und Desert Gold! SCHOCK bei der Evotec Aktie! | Während der Goldpreis schwächelt, befindet sich die Aktie von Desert Gold in einem sauberen Aufwärtstrend. Und geht es nach Analysten, ist eine Vervielfachung möglich. Denn Desert Gold wird in wenigen... ► Artikel lesen | |
| AMGEN | 291,50 | +0,38 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,300 | -0,38 % | Could Viking Therapeutics Be the Next Eli Lilly? | ||
| DEFENCE THERAPEUTICS | 0,302 | +5,96 % | Defence Therapeutics Inc.: Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,381 | -1,80 % | Patentschutz bis 2040: NurExone stärkt seine Exosomen-Produktionstechnologie | ||
| ABIVAX | 109,10 | +3,02 % | Abivax S.A. - 6-K, Report of foreign issuer | ||
| IBIO | 1,551 | -4,90 % | iBio, Inc.: iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors | SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 64,68 | -0,46 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events | Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
BofA Securities 2026 Healthcare Conference May 12-14, 2026
Type:... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,220 | +1,77 % | Voyager Therapeutics, Inc.: Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 | - VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON... ► Artikel lesen | |
| CYBIN | 3,885 | -2,02 % | Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs | Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO... ► Artikel lesen | |
| CAPRICOR | 25,500 | +0,24 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| OPGEN | 1,568 | 0,00 % | CapForce Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| MEREO BIOPHARMA | 0,234 | 0,00 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen | |
| BENITEC BIOPHARMA | 11,400 | +0,35 % | Citizens reiterates Benitec BioPharma stock rating on dose data |
Das Unternehmen POLYPID LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,58 % bei einem Aktienkurs von 4,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.